-
公开(公告)号：US09714225B2
公开(公告)日：2017-07-25
申请号：US15035876
申请日：2014-11-13
发明人： Shriprakash Dhar Dwivedi , Jayprakash Ajitsingh Parihar , Alpeshkumar Pravinchandra Shah , Samir Rameshbhai Gajjar , Brij Khera
IPC分类号： A61K31/55 , C07D223/16
CPC分类号： C07D223/16
摘要： The present invention relates to stable crystalline Form I of lorcaserin hydrochloride of Formula (IA) and processes for its preparation. The invention also relates to processes for the preparation of lorcaserin and pharmaceutically acceptable salts, solvates and hydrates thereof.
-
公开(公告)号：US09708365B2
公开(公告)日：2017-07-18
申请号：US14895432
申请日：2014-06-25
CPC分类号： C07K1/36 , C07K16/065 , C07K16/241 , C07K16/2863 , C07K16/2887 , C07K16/32 , C07K2317/21 , C07K2317/24
摘要： The present invention provides an improved method for the purification of monoclonal antibody from cell culture. Process of purification of the desired monoclonal antibody comprises affinity, hydrophobic interaction and optionally ion exchange column chromatography. It provides more than 99% purity of the desired monoclonal antibody.
-
63.发明授权公开(公告)号：US09636353B2
公开(公告)日：2017-05-02
申请号：US13880092
申请日：2011-10-19
申请人： Ravindra Mittal , Sunilendu Bhushan Roy , Jay Shantilal Kothari , Shafiq Sheikh , Jitendra Dasharathlal Patel , Jinesh Suresh Pancholi
发明人： Ravindra Mittal , Sunilendu Bhushan Roy , Jay Shantilal Kothari , Shafiq Sheikh , Jitendra Dasharathlal Patel , Jinesh Suresh Pancholi
IPC分类号： A61K31/7056 , A61K31/192
CPC分类号： A61K31/7056 , A61K31/192 , A61K2300/00
摘要： The present invention relates to a method for treating, reducing or preventing acne. In particular, the present invention relates to methods for reducing the total number, incidence and severity of acne lesions on the skin which includes both inflammatory and non-inflammatory lesions. Further, the invention relates to reducing the incidence and severity of adverse events resulting from topical application of anti-acne agents resulting in improvement of skin tone. The method includes administering a novel and stable topical anti-acne pharmaceutical composition.
-
64.发明授权公开(公告)号：US09598418B2
公开(公告)日：2017-03-21
申请号：US14647088
申请日：2013-12-23
IPC分类号： C07D498/04 , C07D487/04 , C07D237/32 , C07D491/048 , C07D495/04 , C07D513/04 , C07D403/10
CPC分类号： C07D487/04 , C07D237/32 , C07D403/10 , C07D491/048 , C07D495/04 , C07D498/04 , C07D513/04
摘要： The present invention relates to novel compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to a process of preparing novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
-
公开(公告)号：US09556148B2
公开(公告)日：2017-01-31
申请号：US14910028
申请日：2014-08-06
发明人： Ranjit Desai , Jigar Desai , Pankaj Patel
IPC分类号： C07D401/14 , C07D417/14 , C07D413/14 , C07D403/14 , C07D409/10 , C07D409/14 , C07D498/08 , C07D513/08 , C07D401/12 , C07D403/12 , C07D405/14 , C07D407/12 , C07D407/14 , C07D409/12 , C07D471/08 , C07D491/056 , C07D491/08 , C07D491/107 , C07D495/08
CPC分类号： C07D401/14 , C07D401/12 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/12 , C07D407/14 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D491/056 , C07D491/08 , C07D491/107 , C07D495/08 , C07D498/08 , C07D513/08
摘要： The present invention relates to compounds of general formula (1) that are inhibitors of Janus Kinase (JAK), a family of tyrosine kinases that are involved in inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the compound of the invention inhibits JAK1 and/or JAK2 and/or JAK3 sub families. The present invention also provides methods for the production of the compounds of the invention, pharmaceutical compositions comprising the compounds of the invention, their tautomeric forms, and their pharmaceutically acceptable salts
摘要翻译： 本发明涉及作为炎性病症，自身免疫性疾病，增殖性疾病，变态反应，移植排斥，涉及软骨损害的疾病的酪氨酸激酶家族的Janus Kinase（JAK）抑制剂的通式（1）的化合物 周转，先天性软骨畸形和/或与IL6或干扰素分泌过多相关的疾病。 特别地，本发明的化合物抑制JAK1和/或JAK2和/或JAK3亚族。 本发明还提供了制备本发明化合物的方法，包含本发明化合物，其互变异构形式及其药学上可接受的盐的药物组合物
-
公开(公告)号：US20160200792A1
公开(公告)日：2016-07-14
申请号：US14912984
申请日：2014-08-21
IPC分类号： C07K14/635 , B01D15/36 , C07K1/18
CPC分类号： C07K14/635 , B01D15/363 , C07K1/18
摘要： The present invention relates to improved method for purification of a recombinant parathyroid hormone (rhPTH1-34 or teriparatide), said process for purification of parathyroid hormone comprising following essential steps: (a) Enzymatic cleavage; (b) anion exchange chromatography, followed by other suitable purification steps; wherein step (a) and (b) can be carried out in any order.
摘要翻译： 本发明涉及用于纯化重组甲状旁腺激素（rhPTH1-34或特立帕定）的改进方法，所述方法用于纯化甲状旁腺激素，其包括以下必要步骤：（a）酶切; （b）阴离子交换层析，然后进行其他合适的纯化步骤; 其中步骤（a）和（b）可以以任何顺序进行。
-
公开(公告)号：US09351957B2
公开(公告)日：2016-05-31
申请号：US14677110
申请日：2015-04-02
发明人： Brij Khera , Kumar Kamlesh Singh , Santosh Devidas Diwakar , Chetan Jayantibhai Vasava , Anil Kumar Shivprasad Tiwari
IPC分类号： C07D209/48 , A61K31/4035 , A61K9/14 , A61K9/16
CPC分类号： A61K31/4035 , A61K9/14 , A61K9/146 , A61K9/1652 , C07D209/48
摘要： The present invention provides an amorphous form of apremilast and process for preparation thereof. The present invention also provides a pharmaceutical composition comprising an amorphous apremilast and one or more of pharmaceutically acceptable carriers, excipients or diluents used for the treatment of active psoriatic arthritis.
摘要翻译： 本发明提供了一种无定形形式的去甲生物及其制备方法。 本发明还提供了一种药物组合物，其包含无定形去极化物和一种或多种用于治疗活动性牛皮癣关节炎的药学上可接受的载体，赋形剂或稀释剂。
-
公开(公告)号：US20160058730A1
公开(公告)日：2016-03-03
申请号：US14837195
申请日：2015-08-27
IPC分类号： A61K31/277 , A61K9/28 , A61K9/20
CPC分类号： A61K31/277 , A61K9/2009 , A61K9/2054 , A61K9/2077 , A61K9/2086 , A61K9/2813
摘要： The present invention relates to stable pharmaceutical compositions of teriflunomide or a pharmaceutically acceptable salt thereof. In particular, the invention relates to the stable pharmaceutical compositions of teriflunomide or a pharmaceutically acceptable salt thereof with colloidal silicon dioxide. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of relapsing forms of multiple sclerosis.
摘要翻译： 本发明涉及特氟替尼或其药学上可接受的盐的稳定药物组合物。 特别地，本发明涉及特氟替隆或其药学上可接受的盐与胶体二氧化硅的稳定药物组合物。 本发明还涉及制备这种组合物的方法及其用于治疗复发性多发性硬化症的用途。
-
69.发明申请公开(公告)号：US20160008328A1
公开(公告)日：2016-01-14
申请号：US14796117
申请日：2015-07-10
IPC分类号： A61K31/4245 , A61K31/4035 , A61K9/20
CPC分类号： A61K31/4245 , A61K9/2009 , A61K9/2013 , A61K9/2095 , A61K31/4035 , A61K45/06 , A61K2300/00
摘要： The present invention relates to pharmaceutical package comprising a pharmaceutical preparation comprising azilsartan medoxomil and salts thereof, and a desiccant. Also, relates to a pharmaceutical preparation comprising azilsartan medoxomil and salts thereof and a pH modifier, wherein pH modifier provides a pH range of about 5.5 to about 6.5 when dissolved or suspended in water at a concentration of 1% at 25° C. The invention also relates to processes for the preparation of such pharmaceutical preparation and use thereof for prophylaxis or treatment of circulatory diseases.
摘要翻译： 本发明涉及药物包装，其包含药物制剂，其包含吖唑烷酯和其盐，以及干燥剂。 此外，涉及包含吖唑烷酮莫昔米尔及其盐和pH调节剂的药物制剂，其中pH调节剂在25℃下以1％的浓度溶于或悬浮于水中时，其pH值范围为约5.5至约6.5。本发明 还涉及制备这种药物制剂的方法及其用于预防或治疗循环系统疾病的用途。
-
公开(公告)号：US09119815B2
公开(公告)日：2015-09-01
申请号：US13318701
申请日：2010-05-03
IPC分类号： C12N15/00 , A61K39/165 , A61K39/015 , A61K38/20 , C12N7/00 , A61K35/13 , A61K39/00
CPC分类号： A61K39/165 , A61K35/13 , A61K38/2013 , A61K39/0015 , A61K39/015 , A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/54 , A61K2039/55566 , A61K2039/55588 , A61K2039/575 , A61K2039/70 , C12N7/00 , C12N2760/18421 , C12N2760/18434 , C12N2760/18442 , C12N2760/18443 , Y02A50/412
摘要： A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.
摘要翻译： 描述了包含编码几种恶性疟原虫抗原的异源核酸的包含不同的减毒重组麻疹 - 疟疾载体的麻疹 - 疟疾综合疫苗。 优选地，其涉及包含编码恶性疟原虫的环子孢子（CS）蛋白，恶性疟原虫的裂殖子表面蛋白1（MSP-1）及其衍生物（p-42; p-83- 30-38）以其糖基化和分泌形式，以及恶性疟原虫的顶端膜抗原1（AMA1）以其锚定或分泌形式。 病毒载体源自减毒的麻疹病毒，其基于用作疫苗的菌株，并且有效地传递感兴趣的基因并且有效地结合并感染相关的免疫细胞。
-
-
-
-
-
-
-
-
-
搜索结果
286 条记录 (耗时 0.034 秒)
